Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Nabriva Therapeutics Plc's Business Segments
Nabriva Therapeutics Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 2
Regions Reported
-
Nabriva Therapeutics Plc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product0%
- Grant0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 3 | - |
| Grant | $ 0 | - |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Nabriva Therapeutics Plc
Nabriva Therapeutics Plc is a biopharmaceutical company that develops and commercializes novel therapies to treat serious infections. The company is focused on the development of new antibiotics for the treatment of infections caused by drug-resistant bacteria.
Nabriva was founded in 2006 and is headquartered in Dublin, Ireland, with operations in the United States. The company is traded on the NASDAQ under the ticker symbol "NBRV."
The company's lead product is Xenleta (lefamulin), which is a first-in-class semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired pneumonia (CAP). Xenleta is approved by the FDA in both intravenous (IV) and oral formulations for the treatment of CAP in adults. It is also approved in the European Union for the treatment of community-acquired pneumonia in adults.
In addition to Xenleta, Nabriva has a pipeline of antibacterial agents, including a second-generation pleuromutilin antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI), which is currently in Phase 3 clinical development.
Nabriva also has a research and development collaboration with the Chinese pharmaceutical company, Sinovant Sciences, focused on the development of new drugs to address the growing problem of bacterial resistance in China.
Overall, Nabriva is a clinical-stage biopharmaceutical company focused on the development of innovative antibiotics to combat serious infections caused by drug-resistant bacteria. The company is committed to creating new treatment options for healthcare providers and patients, and to helping address the global public health threat of antibiotic-resistant infections.
Nabriva was founded in 2006 and is headquartered in Dublin, Ireland, with operations in the United States. The company is traded on the NASDAQ under the ticker symbol "NBRV."
The company's lead product is Xenleta (lefamulin), which is a first-in-class semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired pneumonia (CAP). Xenleta is approved by the FDA in both intravenous (IV) and oral formulations for the treatment of CAP in adults. It is also approved in the European Union for the treatment of community-acquired pneumonia in adults.
In addition to Xenleta, Nabriva has a pipeline of antibacterial agents, including a second-generation pleuromutilin antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI), which is currently in Phase 3 clinical development.
Nabriva also has a research and development collaboration with the Chinese pharmaceutical company, Sinovant Sciences, focused on the development of new drugs to address the growing problem of bacterial resistance in China.
Overall, Nabriva is a clinical-stage biopharmaceutical company focused on the development of innovative antibiotics to combat serious infections caused by drug-resistant bacteria. The company is committed to creating new treatment options for healthcare providers and patients, and to helping address the global public health threat of antibiotic-resistant infections.
Nabriva Therapeutics Plc is a specialized biopharmaceutical company that is dedicated to the research, development, and commercialization of innovative antibiotics, particularly targeting serious and life-threatening bacterial infections. With a strong commitment to addressing the growing challenge of antibiotic resistance and the urgent medical needs associated with severe bacterial infections, Nabriva positions itself as a key player in the field of antibiotic therapy.
Segments
Nabriva Therapeutics operates through two primary segments that focus on different aspects of antibiotic treatment:
1. Hospital/IV Products:
- This segment is concentrated on the development and commercialization of intravenous (IV) antibiotics. The products in this segment are specifically designed to address serious infections that often require hospitalization. The company’s pipeline includes multiple antibiotic candidates that are at various stages of development, emphasizing efficacy against resistant bacterial strains commonly found in hospital settings. The need for potent IV antibiotics is critical, as hospital-acquired infections can often be severe and complicated by resistant pathogens.
2. Outpatient/Oral Products:
- The outpatient products segment focuses on the development of oral antibiotic treatments suitable for patients who do not require hospitalization. This segment addresses community-acquired infections, which are prevalent in outpatient settings. Products being developed target common but serious conditions such as community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTIs), aiming to provide effective and convenient treatment options outside of the hospital environment.
Products
Nabriva has an emerging portfolio of antibiotic products, with a focus on innovative therapies that have distinct mechanisms of action, allowing them to combat resistant bacteria effectively. The key products include:
1. Xenleta (lefamulin):
- Xenleta represents a pioneering addition to the antibiotic landscape as a first-in-class agent approved by the FDA for the treatment of community-acquired bacterial pneumonia (CABP). It functions by inhibiting bacterial protein synthesis, thus preventing the growth and replication of bacteria. The introduction of Xenleta provides a promising alternative for patients, particularly in light of the challenges posed by antibiotic resistance.
2. Contepo (fosfomycin):
- Contepo is an intravenous formulation of fosfomycin, a broad-spectrum antibiotic designed for the treatment of complicated urinary tract infections, including those caused by multidrug-resistant pathogens. Its approval by the FDA highlights its potential in addressing pressing medical needs, especially in hospital environments where such resistant infections are prevalent.
3. BC-7013:
- BC-7013 is an oral antibiotic in development aimed at treating community-acquired bacterial pneumonia. As a member of the pleuromutilin class of antibiotics, it showcases Nabrivas commitment to developing novel therapies that can effectively manage bacterial infections in an outpatient context, improving patient compliance and treatment outcomes.
Services
Nabriva Therapeutics provides a complementary suite of services designed to facilitate the efficient development and commercialization of its antibiotic products:
1. Clinical Research:
- The company undertakes rigorous clinical trials to assess the safety, efficacy, and pharmacokinetics of its antibiotic candidates. This research is crucial in gathering the necessary data to support product approvals and demonstrates Nabriva’s commitment to maintaining high standards of scientific integrity.
2. Regulatory Affairs:
- Nabriva’s regulatory affairs team collaborates closely with health authorities to navigate the complex regulatory pathways required for product approval. This includes preparing and submitting regulatory submissions and ensuring compliance with local guidelines in various markets.
3. Commercialization:
- With a dedicated commercialization team, Nabriva focuses on the effective marketing and distribution of its products to healthcare providers, hospitals, and pharmacy networks. This team works to establish strategic partnerships and presence in the market, facilitating access to innovative antibiotic therapies.
4. Medical Affairs:
- The medical affairs department within Nabriva plays a pivotal role in supporting clinical guidelines and educating healthcare practitioners about the safe and effective use of their products. This team provides scientific insights and addresses inquiries regarding clinical applications, further enhancing the understanding and usage of Nabrivas antibiotics.
In summary, Nabriva Therapeutics Plc stands out as a biopharmaceutical innovator primarily dedicated to fighting the rising tide of antibiotic resistance through its strategic focus on novel antibiotics. The company’s structured segments, targeted products, and supportive services signify its comprehensive approach to addressing the critical and growing unmet needs in the treatment of serious bacterial infections.
Segments
Nabriva Therapeutics operates through two primary segments that focus on different aspects of antibiotic treatment:
1. Hospital/IV Products:
- This segment is concentrated on the development and commercialization of intravenous (IV) antibiotics. The products in this segment are specifically designed to address serious infections that often require hospitalization. The company’s pipeline includes multiple antibiotic candidates that are at various stages of development, emphasizing efficacy against resistant bacterial strains commonly found in hospital settings. The need for potent IV antibiotics is critical, as hospital-acquired infections can often be severe and complicated by resistant pathogens.
2. Outpatient/Oral Products:
- The outpatient products segment focuses on the development of oral antibiotic treatments suitable for patients who do not require hospitalization. This segment addresses community-acquired infections, which are prevalent in outpatient settings. Products being developed target common but serious conditions such as community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTIs), aiming to provide effective and convenient treatment options outside of the hospital environment.
Products
Nabriva has an emerging portfolio of antibiotic products, with a focus on innovative therapies that have distinct mechanisms of action, allowing them to combat resistant bacteria effectively. The key products include:
1. Xenleta (lefamulin):
- Xenleta represents a pioneering addition to the antibiotic landscape as a first-in-class agent approved by the FDA for the treatment of community-acquired bacterial pneumonia (CABP). It functions by inhibiting bacterial protein synthesis, thus preventing the growth and replication of bacteria. The introduction of Xenleta provides a promising alternative for patients, particularly in light of the challenges posed by antibiotic resistance.
2. Contepo (fosfomycin):
- Contepo is an intravenous formulation of fosfomycin, a broad-spectrum antibiotic designed for the treatment of complicated urinary tract infections, including those caused by multidrug-resistant pathogens. Its approval by the FDA highlights its potential in addressing pressing medical needs, especially in hospital environments where such resistant infections are prevalent.
3. BC-7013:
- BC-7013 is an oral antibiotic in development aimed at treating community-acquired bacterial pneumonia. As a member of the pleuromutilin class of antibiotics, it showcases Nabrivas commitment to developing novel therapies that can effectively manage bacterial infections in an outpatient context, improving patient compliance and treatment outcomes.
Services
Nabriva Therapeutics provides a complementary suite of services designed to facilitate the efficient development and commercialization of its antibiotic products:
1. Clinical Research:
- The company undertakes rigorous clinical trials to assess the safety, efficacy, and pharmacokinetics of its antibiotic candidates. This research is crucial in gathering the necessary data to support product approvals and demonstrates Nabriva’s commitment to maintaining high standards of scientific integrity.
2. Regulatory Affairs:
- Nabriva’s regulatory affairs team collaborates closely with health authorities to navigate the complex regulatory pathways required for product approval. This includes preparing and submitting regulatory submissions and ensuring compliance with local guidelines in various markets.
3. Commercialization:
- With a dedicated commercialization team, Nabriva focuses on the effective marketing and distribution of its products to healthcare providers, hospitals, and pharmacy networks. This team works to establish strategic partnerships and presence in the market, facilitating access to innovative antibiotic therapies.
4. Medical Affairs:
- The medical affairs department within Nabriva plays a pivotal role in supporting clinical guidelines and educating healthcare practitioners about the safe and effective use of their products. This team provides scientific insights and addresses inquiries regarding clinical applications, further enhancing the understanding and usage of Nabrivas antibiotics.
In summary, Nabriva Therapeutics Plc stands out as a biopharmaceutical innovator primarily dedicated to fighting the rising tide of antibiotic resistance through its strategic focus on novel antibiotics. The company’s structured segments, targeted products, and supportive services signify its comprehensive approach to addressing the critical and growing unmet needs in the treatment of serious bacterial infections.